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Abstract Novel and powerful technologies such as DNA
microarrays and proteomics have made possible the analysis of
the expression levels of multiple genes simultaneously both in
health and disease. In combination, these technologies promise to
revolutionize biology, in particular in the area of molecular
medicine as they are expected to reveal gene regulation events
involved in disease progression as well as to pinpoint potential
targets for drug discovery and diagnostics. Here, we review the
current status of these technologies and highlight some studies in
which they have been applied in concert to the analysis of biopsy
specimens. ß 2000 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
It is now a little more than 10 years since the Human
Genome Project was launched and during this relatively short
period of time there have been remarkable advances in the
construction of physical and genetic maps as well as in the
identi¢cation of genes associated with human diseases [1,2].
Soon, the total sequence of the human genome will be deci-
phered and, hopefully, made available to researchers world-
wide for the bene¢t of mankind.
Undoubtedly, the Human Genome Project has paved the
way to the revolution in the life sciences that we are experi-
encing today. Gradually, however, its focus is starting to shift
towards functional genomics, an area of the post-genomic era
that deals with the functional analysis of genes and their
products (see the article by Go¡eau in this issue). Techniques
of functional genomics include methods for gene expression
pro¢ling at the transcript (DNA microarrays [3^5] ; see also
article by Brazma and Vilo in this issue); di¡erential display
[6] ; serial analysis of gene expression [7^9], and protein levels
(proteomics) ([10^12] ; see also article by Andersen and Mann
in this issue), as well as transgenics [13], phage display [14],
procedures for studying protein^protein interactions ([15,16];
see also article by Legrain and Selig in this issue) and bioin-
formatics [17].
Among the techniques of functional genomics, both DNA
microarrays ([3^5] and references therein) and proteomics [10^
12] hold great promise for the study of complex biological
systems with applications in molecular medicine. These novel
and powerful gene expression pro¢ling techniques permit the
analysis of the expression levels of thousands of genes simul-
taneously both in health and disease. These technologies are
complementary, allow high-throughput, and in combination
are expected to generate a vast amount of gene and protein
expression data that may lead to a better understanding of the
regulatory events involved in normal and disease processes. In
addition, these technologies o¡er a systematic approach for
searching for e¡ective targets for drug discovery and diagnos-
tics.
Here, we review the current state of DNA microarrays and
proteomics and highlight some studies in which they have
been applied in concert to the analysis of biopsy specimens.
2. DNA microarrays
The amount of information that is now becoming available
to researchers in the life sciences is exploding, and even
though the data can be stored in conventional media, new
methods are being required to analyze large sets of genes in
a high-throughput fashion. For this purpose the DNA array
technology was developed. The method makes it possible to
survey thousands of genes in parallel, and has several areas of
application. One is expression monitoring [18], in which the
transcript levels of genes are measured in di¡erent physiolog-
ical conditions both in cultured cells and tissues, to search for
regulatory expression patterns. Understanding patterns of ex-
pressed genes is expected to improve our knowledge of highly
complex networks that cross communicate in hitherto un-
known ways both in health and disease. Another area of
application is polymorphism analysis [19]. In this case, poly-
morphic regions of the genome are scanned to search for link-
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age to diseases, and to reveal disease susceptibility genes and/
or inherited disease genes. A similar approach has been used
to analyze polymorphic regions of known genes, in particular
to determine whether polymorphisms are associated with an
altered function of the gene product, a fact that may increase
the susceptibility to disease. Finally, various attempts have
been made to utilize DNA arrays for sequencing [20].
Below we review the technology currently in use for micro-
array-generated gene expression pattern discovery as well as
some applications. Table 1 provides a set of World Wide Web
sites that contain useful additional information (see also the
article by Brazma and Vilo in this issue).
2.1. Microarray technology
Microarrays are usually made by deposition of DNA spots
on a solid support like a coated glass surface, that di¡ers in
several ways from conventional ¢lter-based supports such as
charged nylon and nitrocellulose. The £atness of the glass
surface makes it possible (i) to array molecules in a parallel
fashion, (ii) to miniaturize the procedure and (iii) to use £uo-
rescent dyes for detection. There is no di¡usion of the applied
material into the support, thus allowing focusing for laser
scanning microscopy.
Two main procedures have been used to produce DNA
chips: photolithography as developed and marketed primarily
by A¡ymetrix Inc. (Santa Clara, CA, USA) [20,21] and me-
chanical gridding [22]. Photolithography is well known in the
computer chip industry and utilizes an ultraviolet light source
that passes through a mask that directs in a step-wise manner
where a photochemical reaction (oligonucleotide synthesis)
takes place on a siliconized glass surface. The mask can be
produced with openings as small as a few micrometers allow-
ing a density of several hundred thousand probes per square
centimeter of glass. There is, however, an inherent length re-
striction with this in situ synthesis technology limiting the
probes to about 25 nucleotides in length. High-density arrays,
on the other hand, allow the use of multiple probes per gene
[20].
Mechanical gridding methods are based on ink-jet or phys-
ical deposition of the material using pins manufactured with
very high precision. There is direct surface contact and the
transport of small amounts of liquid makes these systems
susceptible to evaporation and contamination with dust par-
ticles. The gridding instruments use an XYZ motion control
based on step engines that can be controlled with very high
precision. The DNA containing material can be spotted from
96 or 384 well plates to glass in prede¢ned patterns.
The arrayed probes can be oligos (photolithography and
gridding) or cDNAs (gridding). The hybridization reaction
conditions are quite di¡erent in the two cases, and special
sample preparations are needed to optimally utilize these
probes. With shorter probes, i.e. of 20^50 nucleotides, the
sample is fragmented to avoid tertiary structures and to
achieve optimal hybridization [18,20]. Polymerase chain reac-
tion (PCR) ampli¢ed probes of 300^2000 nucleotides usually
do not require fragmentation of the sample [23].
The type of glass used as support, the coating substance,
the coupling technique, the labelling system, and the £uores-
cent labels used for detection are all variables that must be
optimized. A number of coating substances are commercially
available to immobilize DNA to the surface. Two types of
slides are available that use a coating procedure designed
for printing of amine modi¢ed DNA: these include (i) sily-
lated slides, which contain reactive aldehyde groups that react
with amino-groups via a Schi¡ base formation as the printed
DNA dries on the surface of the slide (available from Tele-
chem Inc., CA, USA; Cell Associates Inc., TX, USA; for
coupling chemistry see http//www.arrayit.com/microarray-
coupling/) and (ii) activated slides prepared by the covalent
attachment of a hydrophilic, polymeric amine reactive coating
to silane base-coated slides as described by Beier and Hoheisel
[24] (available from Surmodics Inc., MS, USA). Amine-modi-
¢ed DNA attaches covalently to the activated polymeric sur-
face.
Three other types of slides are available that are based on
more conventional immobilization technology routinely used
in membrane immobilization: these include (i) silanized slides
which carry covalently attached primary amines on the sur-
face that can form ionic bonds with the phosphate backbone
at neutral pH. In addition, the radical-based coupling between
thymidine residues on the DNA and carbons on the alkyl
amine of the substrate can be induced with UV or heat (pro-
vided by companies like Telechem Inc., CA, USA; Sigma
Aldrich, Inc., MO, USA; Corning, Inc., NY, USA), (ii) nitro-
cellulose-based polymer-coated slides that possess the binding
and immobilization properties of nitrocellulose that binds
DNA in a non-covalent but irreversible manner (Schleicher
and Schuell), and (iii) poly-lysine-coated slides which require
UV crosslinking of the DNA (available from Sigma Aldrich
Inc., MO, USA; see also http//cmgm.stanford.edu/pbrown/
protocols/1_slides.html).
2.2. Quantitating the signals from arrays
A linear response that covers two or three orders of mag-
nitude is often needed to detect low and high copy number
transcripts on the same array. In cases where this is not pos-
sible it may be necessary to scan the chip at di¡erent wave-
lengths, or to amplify the signal with an immune sandwich on
top of the bound sample [25]. In the latter case, the ¢rst
scanning is carried out after hybridization of the labelled sam-
ple, and the second after reaction with the labelled antibodies.
It is necessary to document the linearity and reproducibility
in each step of the procedure, and sometimes even from probe
to probe to obtain reliable data. Often, a standard sample is
used to compare with the experimental sample and this may
compensate for di¡erences in hybridization from probe to
probe.
2.3. Standardization
Comparison of data obtained from independent arrays and
from di¡erent laboratories requires standardization. Both the
A¡ymetrix chips and the custom made cDNA chips use di¡er-
ent methods for standardization. The A¡ymetrix chips have
approximately 20 probes per gene and standardization is ei-
ther based on the expression level of selected genes, like actin
and GAPDH, or on a setting of the global chip intensity to
approximately 150 units per gene on the chip. In this way,
chip data from di¡erent experiments can be compared to each
other. In our hands, the data obtained with the two standard-
ization methods di¡er only by approximately 10% (unpub-
lished observations).
The custom-made cDNA or oligo arrays also require stan-
dardization, but this is a complex problem. In general, the
standard used often re£ects the purpose for which the array
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was produced. For example, for expression monitoring of
breast cancer cells, a mixture of breast cancer cell lines may
provide a good standard [26]. Today, however, there is no
golden standard that can be used for all purposes and as a
result, it is di⁄cult to compare data from di¡erent laborato-
ries and often it is necessary to use other technologies such as
Northern hybridization, real-time PCR or immunostaining to
validate the signals. A minimum requirement is that labora-
tories that produce arrays themselves should be able to repro-
duce data from one chip generation to the next based on the
analysis of well-de¢ned controls covering di¡erent genes and
expression levels. In addition, it is common to use spiking of
samples with bacterial genes that hybridize to probes spotted
for control purpose on the arrays.
2.4. Samples for expression monitoring
The analysis of relatively homogeneous cell populations
(cloned cell lines, yeast, etc.) has proven much simpler than
the analysis of tissue biopsies as the latter often contain many
cell types (epithelial, endothelial, in£ammatory, nerve, muscle,
and connective tissue cells) that are present in variable
amounts. Standardization may require microdissection of
the tissue to isolate speci¢c cell types [27,28], although the
number of cells needed for the assay is well above a million.
Sampling of speci¢c cell types using laser capture microdissec-
tion (LCM) [29] can be a time-consuming task, and given that
mRNA is prone to degradation the processing time must be
kept to a minimum. If only a small amount of material is
available, then a reverse transcription-PCR step is necessary
for ampli¢cation, but this adds an additional complication
due to the lack of linear ampli¢cation of all transcripts. In
one of our laboratories we have used preparations of single
cell types from tumor biopsies to standardize pooling of sam-
ples for generating pro¢les of gene expression at di¡erent
stages of tumor development (manuscript in preparation).
2.5. Bioinformatic analysis of expression data
2.5.1. Hierarchical cluster algorithms. Hierarchical cluster-
ing algorithms can be divided into two types: agglomerative
and divisive (Fig. 1) [30]. The agglomerative method is a bot-
tom-up approach, where the algorithm starts with n separate
clusters (for example 4000 genes, where n = 4000) and succes-
sively combines clusters until only one is left. The divisive
method, on the other hand, is a top-down approach starting
with one cluster and successively splitting clusters to produce
others. The algorithm used to form the clusters must also be
de¢ned: two widely used and simple algorithms are the single
linkage and average linkage methods, respectively. Single link-
age, also called nearest neighbor, de¢nes the distance between
two clusters as the minimum distance over all pairs of clusters.
Average linkage takes in consideration the average distance
over all [30].
A distance matrix must be calculated before clustering is
performed, and it is the distances between the obtained gene
expression pro¢les that are used to form the actual clusters
[30]. Observations with small distances are grouped together
as described above. The two most commonly used distance
measurements are the Euclidean distance and the Pearson
correlation coe⁄cient.
Euclidean distance : ED 

X ik3X jk
q
2
Pearson correlation coe⁄cient:
Pearson 

X ik3X jk2
Vk
s
Xik is the measurement for the kth variable on sampling unit i.
Vk is the variance of the kth variable [30,31].
2.5.2. Non-hierarchical cluster algorithms. In non-hier-
archical cluster analysis it is assumed that the data can be
divided into a certain number of clusters and that they are
well separated. The advantage of this approach is that large
data sets can be clustered much faster than by using hierarchi-
cal clustering because a lower number of clusters is assigned.
The most common method for non-hierarchical cluster anal-
ysis is k-means. However, a method termed self-organized
maps (SOM) has recently been applied to expression data
generated from DNA chip arrays [32,33]. The k-means meth-
od [34] identi¢es k points that function as cluster centers.
Each data point is then assigned to one of these centers in a
way that minimizes the sum of the distances between all
points and their centers. Thus, it is the distribution of points
that decides the value of the means. One drawback of this
method is that a speci¢c number of clusters is assigned, as
the number of clusters is usually unknown in large data
sets. SOM is similar to the k-means approach, but it has a
geometrical con¢guration and the number of nodes prede¢nes
this con¢guration. Initially, data points are mapped onto the
geometrical con¢guration. When clustering the data with
SOM the position of a node migrates to ¢t the data points
during successive iterations [32,33].
2.5.3. Supervised classi¢cation. Common to the clustering
methods in which array data are used is that they are unsu-
pervised, i.e. no prede¢ned references are known. An alterna-
tive option is to construct a supervised classi¢cation method
that requires at least two references. For cancer classi¢cation,
for example, the references could be the gene expression pro-
¢les from normal and invasive tumor tissue. In this particular
case, a vector representing gene expression over n genes can be
used to describe each tissue [35,36]. In a recent article by
Golub and co-workers [36], the authors analyzed 6817 genes
using 38 bone marrow samples. Based on these 38 samples
they found that a vector based on 10 and 200 genes was
su⁄cient to distinguish between acute myeloid leukemia and
acute lymphoblastic leukemia. Thus, the authors were able to
construct a cancer classi¢er based on a low number of genes.
Using a similar vector-based classi¢er approach, Brown and
coworkers [37] analyzed 2467 yeast genes in 79 di¡erent ex-
periments and were able to classify genes into functional cat-
egories based on the expression data from DNA chip arrays.
Fig. 1. Two main types of clustering algorithms, the hierarchical
and the non-hierarchical algorithms.
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2.6. Applications of arrays for expression monitoring
One of the main areas for array application is in the simul-
taneous monitoring of thousands of transcripts in di¡erent
biological settings. The approach is being used to identify
new networks and to understand patterns of expressed genes.
A number of articles have been published using the array
technology aiming at identifying disease-associated alterations
in humans. For this purpose clinical samples, human cell lines,
and in a few cases animal models of human disease have been
used.
2.6.1. Gene expression pro¢ling of tissue biopsies, cell lines
and animal models of disease. 2.6.1.1. Tissue biopsies. Gene
expression studies on clinical samples have been performed in
breast and colon cancer [26,38], as well as in atherosclerosis
[39,40]. Genes of presumably known functions have been
identi¢ed and linked to the diseases; most of these data are
now available in the Internet (Table 1). In a study of breast
cancer that used clinical specimens and cell lines, with an
array containing approximately 5000 genes, Perou and col-
leagues [26] identi¢ed a proliferation related gene cluster in
the cell line that was upregulated in the more aggressive clin-
ical breast tumor specimens [26]. In a similar study of colon
cancer based on the A¡ymetrix arrays, 48 EST’s homologous
to ribosomal proteins were found to be unregulated in the
tumor tissue [38]. In this study, a muscle index was used for
correcting for the stromal components as this showed a high
index in the normal biopsies. Both the breast and the colon
cancer studies lacked a correlation between gene expression
levels in the cell lines and in the clinical specimens.
Human atherosclerosis lesions from arteria carotis sampled
from patients undergoing surgery have also been analyzed
using the A¡ymetrix expression arrays [40]. One important
¢nding was a ¢ve-fold upregulation of the early growth re-
sponse gene Egr-1, a DNA binding protein that in£uences the
transcription of genes encoding growth factors, cytokines, ad-
hesion molecules, and proteins related to coagulation. This
¢nding was corroborated by immunohistochemistry and ani-
mal experiments, and identi¢ed Egr-1 as a possible target for
therapeutic intervention.
2.6.1.2. Cell lines. Several studies based on expression
monitoring have been performed in human cell lines in areas
as diverse as cancer [41], ophthalmology [42], and the central
nervous system [43]. Arrays have also been used to study the
e¡ect of cytokines (interferons) [44], cytomegalovirus infection
[45], and oncogene transfection [46] on the overall patterns of
gene expression. In one study, human foreskin ¢broblasts
were infected with human cytomegalovirus and the expression
of approximately 6000 genes was monitored for up to 24 h
[45]. A total of 258 genes was found to be upregulated more
than four-fold. These included HLA-E (upregulated six-fold),
a protein that protects against cytotoxic T-lymphocytes; RO/
SSA (52 kDa protein mRNA; upregulated 12-fold), a com-
monly targeted autoantigen, as well as several components of
the pathway that produce prostaglandin E2 from arachidonic
acid. In another study, it was shown that treatment of the
human ¢brosarcoma cell line HT 1080 with IFNs K, L and
Q resulted in the upregulation of novel genes implicated in
apoptosis (RAP46, Bag-1, scramblase), while genes like
IGF-2 and ZnT-3 were strongly downregulated [44].
The e¡ect on gene expression of the fusion oncogene PAX3-
FKHR transfected into NIH 3T3 cells has also been studied
using microarrays [46]. It was shown that the fusion gene, but
not the wild type control was able to activate a myogenic
transcription program that included induction of a number
of transcription factors such as MyoD, myogenin, Six1, and
Slug.
2.6.1.3. Animal model systems. A common approach to
the study of human diseases is to use animal model systems.
This has been done for a range of diseases including encepha-
lomyelopathy, lymphoma, renal tubuli [23], and lung ¢brosis
[47]. In the latter case, A¡ymetrix chips were probed with
pooled samples obtained from groups of six animals to reduce
variations and cost. Transcripts that were signi¢cantly altered
in lung ¢brosis [47] included extracellular matrix and in£am-
matory response genes. Analysis of clusters containing these
genes in a time course experiment with the SPOTFIRE PRO
3.0 program revealed di¡erent temporal patterns of expression
that further subdivided these genes.
2.6.2. Toxicology and drug testing. From a toxicological
point of view, there are great expectations for expression mon-
itoring as the e¡ect of drugs, both expected and unforeseen
side e¡ects, can be monitored in animals and eventually in
humans [48,49]. One problem that has arisen from these
studies, even in quite simple model systems, is the often-
unexplained changes in transcript levels observed. These
changes are quite reproducible, suggesting a much more com-
plex relationship among gene products than previously
thought [49].
The combination of gene expression monitoring and testing
of drugs on cell lines and in animal models holds great prom-
ise. A recent publication showed that the variation in the liver
expression of genes encoding xenobiotic metabolizing en-
zymes, glutathione regulators, DNA repair enzymes, heat
shock proteins and housekeeping genes is larger among indi-
vidual animals than that introduced by the array assay itself
[49]. These studies revealed the upregulation of cytochromes
even at low doses of L-naphtho£avone treatment and showed
a good correlation between the array and Northern hybridi-
zation data. A recent screening using cDNA microarrays of 60
human cell lines used by the National Cancer Institute for
Table 1
Useful links on the World Wide Web for array data and software for data analysis
Ref. Link Available
[1] http://llmpp. nih.gov/lymphoma/ data and software
[3] http://www.cse.ucsc.edu/research/compbio/genex/genex.html data and software
[6,12,17,18] http://www.genome.wi.mit.edu/MPR/data_sets.html data and software (GeneCluster)
[11] http://www.rii.com/tech/pubs/nm41293.htm data
[13] http://arep.med.harvard.edu/network_discovery/ data (results)
[14] http://quantgen.stanford.edu/ data (results)
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drug discovery, has formed the basis for establishing a data-
base that can be linked to gene expression data and molecular
pharmacology [41,50].
2.6.3. Molecular classi¢cation of diseases. Classi¢cation of
diseases can generally be achieved by class discovery and class
prediction [36]. Class discovery refers to the identi¢cation,
based on gene expression, of previously unrecognized sub-
types of the disease. If clinical follow-up material is available
these classes can be related to signs and symptoms, disease
course, treatment outcome, and mortality. Class prediction
refers to the ability to assign a particular patient to an already
de¢ned class, based on molecular examination of the diseased
tissue or other specimens.
Two recent examples have demonstrated the power of ex-
pression arrays to classify hematological malignancies. In one
of these studies, leukemias were classi¢ed as AML and ALL,
respectively, based on 50 genes selected from an array carry-
ing 6817 genes. In this study, 36 out of 38 patients were
correctly classi¢ed, and two were uncertain. The 50 genes
used in the array included some that were known to di¡er
between AML and ALL, as well as new markers [36].
Another study classi¢ed B-cell lymphomas into two molec-
ularly distinct classes that re£ected di¡erent stages of B-cell
di¡erentiation, the germinal center-like and activated B-cell
like lymphoma groups, respectively. For this study the lym-
phochip microarray from Research Genetics, which holds
17 856 genes, was used. Follow-up for 12 years showed a sig-
ni¢cant di¡erence in survival among these groups [51].
It is envisaged that global surveys of gene expression will
identify marker genes that may be used to group patients into
molecularly relevant categories; these markers are expected to
greatly improve the precision and power of clinical trials.
2.7. Conclusions
There is no doubt that the massive parallel gene expression
information generated by microarrays will have a major im-
pact in the discovery and understanding of patterns of ex-
pressed genes. In addition, the technology is expected to gen-
erate novel and e¡ective targets for drug discovery and
provide, in combination with proteomics, valuable tools for
the entire process of drug development and evaluation.
One of the main challenges we foresee in the future will be
to solve the problems posed by the analysis, interpretation
and access to the large amount of information that will be
generated. Large studies of EST’s have not been published yet
as data analysis requires the development of new bioinfor-
matic tools that can deal with the huge amount of informa-
tion that is being created. These studies are expected to iden-
tify new genes of importance to speci¢c biological processes
and reveal new regulatory pathways through the analysis of
the expression levels of individual EST’s in large numbers of
samples.
In the future, coupling of expression monitoring to trans-
genic animal models may prove to be quite rewarding as the
global e¡ect of a gene knock-out or knock-in can be moni-
tored with both microarrays and proteomics tools [10].
3. Proteomics
A complementary technology to DNA microarrays for
monitoring gene expression is provided by proteomics, a
term generally used to encapsulate all of the technology cur-
rently available to analyze global patterns of gene expression
at the protein level. Proteins are frequently the functional
molecules and, therefore, the most likely to re£ect di¡erences
in gene expression. Genes may be present, they may be mu-
tated, but they are not necessarily transcribed. Some messen-
gers are transcribed but not translated, and the number of
mRNA copies does not necessarily re£ect the number of func-
tional protein molecules [52]. In addition, proteomics ad-
dresses problems that cannot be approached by DNA analy-
sis, namely, relative abundance of the protein product, post-
translational modi¢cation, subcellular localization, turnover,
interaction with other proteins as well as functional aspects.
The proteome has been de¢ned by Wilkins and colleagues
as the complete set of proteins encoded by the genome [53],
and recently, the term has been broadened to include the set
of proteins expressed both in space and time. There are two
main approaches to proteomics: one is the expression model
in which all proteins are analyzed, and the other is the cell
map model in which only a selected set of proteins, like com-
plexes and organelles, are studied [54].
The proteomic technology is complex, and comprises a
plethora of state of the art techniques to resolve (high reso-
lution two-dimensional gels), quantitate (phosphorimager,
special scanners), identify and characterize proteins (microse-
quencing, mass spectrometry), as well as to store (two-dimen-
sional polyacrylamide gel electrophoresis (2D PAGE) data-
bases; http://biobase/dk/cgi-bin/celis ; http://expasy.hcuge.ch/
sprot/sprot-top.html) communicate and interlink protein and
DNA sequence and mapping information (bioinformatics)
[10,12,55^58]
The usefulness of the 2D PAGE technique for large-scale
proteomic projects depends very much on the number of pro-
teins that can be resolved in a complex protein mixture, for
example a human cell. Proteome pro¢le data from a few lab-
oratories, including one of our own, have indicated that only
a fraction of the human genes are switched-on in a given cell
type and extensive analysis of whole cell extracts, organelles as
well as partially puri¢ed subcellular fractions, suggest that
individual cells may not express more than 6000 primary
translation products [59]. To this number one has to add
the post-translational processing and chemical modi¢cations
(phosphorylation, glycosylation, demethylation, acetylation,
myristoylation, palmitoylation, sulfation, ubiquination, etc.),
the latter being rather common and extensive in many pro-
teins [60,61]. Thus, as we stand today the 2D PAGE technol-
ogy is not able to resolve and depict in a single gel all of the
proteins thought to be present in a mammalian cell.
Currently, there is a great deal of interest in proteomics as
applications of this technology are expected to reveal gene
regulation events involved in disease progression as well as
potential targets for drug discovery and diagnostics. More-
over, the technology is bound to have a great impact in agri-
culture, toxicology and the industry in general.
3.1. Protein separation: the 2D PAGE technology
For the past 24 years, high resolution 2D PAGE has been
the technique of choice for analyzing the protein composition
of cells, tissues and £uids, as well as for studying changes in
global patterns of gene expression elicited by a wide array of
e¡ectors [12,62^64]. The technique, which was originally de-
scribed by O’Farrell [65,66] and Klose [67], separates proteins
both in terms of their isoelectric point (pI) and molecular
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weight and provides the highest resolution for protein analy-
sis. Usually, one chooses a condition of interest, for example
the addition of serum to non-di¡erentiated human keratino-
cytes, or compare normal and transformed cells (Fig. 2A,B),
and let the cells reveal the global protein response as all de-
tected proteins can be analyzed both qualitatively (post-trans-
lational modi¢cations) and quantitatively (relative abundance,
co-ordinated expression, Fig. 2C) in relation to each other
([55,68] and references therein; see also http://biobase.dk/
cgi-bin/celis).
For many years the 2D PAGE technology relied on the use
of carrier ampholytes (amphoteric compounds) to establish
the pH gradient, but this technique has proven to be di⁄cult
because of the lack of reproducibility created by uncontrol-
lable variations in the batches of ampholytes used to generate
the pH gradients. Lately, however, with the introduction of
immobilized pH gradients (IPGs) [69,70], which are integral
part of the polyacrylamide matrix, it has been possible to
obtain focusing patterns that can be easily reproduced by
the non-expert. IPGs avoid some of the problems associated
with carrier ampholytes such as cathodic drift and endosmo-
sis, allow a higher loading capacity for micropreparative runs,
and provide increased charge resolution when narrow pH gra-
dients (0.03 pH unit/cm) are used ([70,71] and references
therein). In our hands, however, carrier ampholytes (3.5^10,
Fig. 3A) and broad range IPGs (Fig. 3B) resolve similar num-
ber of [35S]methionine labelled polypeptides (about 2500) as
illustrated with the separation of whole protein extracts from
labelled human keratinocytes [72]. It has been proposed that
narrow range, overlapping IPG gradients viewed side-by-side
may provide a solution to the problem of resolving and de-
picting the proteome of a given cell type. Recently, however,
Corthals and co-workers found this solution unrealistic, as it
will require the running of a huge number of gels [71]
Very basic polypeptides have proven di⁄cult to resolve,
although both carrier ampholytes (non-equilibrium pH gra-
dient electrophoresis, NEPHGE) [66,73] and IPGs (9^12 and
4^12) ([70] and references therein) have been shown to sepa-
rate basic proteins.
One of the most important steps in the 2D PAGE technol-
Fig. 2. A and B: IEF 2D gels of non-cultured (A) and SV40-transformed (B) human keratinocytes. Only a fraction of the gels are shown. C:
Manual quantitations (scintillation counting) of some of the proteins shown in (A) and (B). Proteins indicated with red are upregulated, those
indicated with blue are downregulated, while those indicated with green are una¡ected. From Celis and Olsen [68].
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ogy concerns sample preparation as very often some proteins
cannot be properly dissolved by the lysis solution originally
developed by O’Farrell [65]. Thus, there is pressing need to
develop protocols for optimizing sample solubilization. To-
wards this aim, Rabilloud and co-workers have made use of
the high loading capacity of IPGs to resolve membrane pro-
teins for structural analysis, and in doing so have improved
their solubility by using a combination of detergents and cha-
otropes [74,75]. It has been shown that the addition of thio-
urea, CHAPS and sulfobetain surfactants to the lysis solution
containing urea results in a much improved solubilization as
well as transfer to the second dimension SDS gel. As far as
nuclear proteins are concerned, Go«rg and colleagues have
improved considerably the separation of very basic proteins
by ¢rst precipitating the samples with acetone prior to solubi-
lization in the lysis solution [70]. The problems associated
with the extraction of tissue samples, on the other hand, are
much more complex and have not been addressed yet in a
systematic fashion.
3.1.1. Detection. An important limitation of the 2D
PAGE technology is the lack of very sensitive procedures to
detect those proteins that are present in very low abundance.
In addition, detection procedures are needed that can be ap-
plied to a large number of resolved proteins whose abundance
may span through seven or eight orders of magnitude.
Clearly, the sensitivity of silver nitrate and Coomassie Blue
staining is inadequate, and only metabolic labelling with spe-
ci¢c isotopes may reveal enough proteins to warrant proteo-
mic projects. Furthermore, the use of phosphor-imaging tech-
nology may enhance the sensitivity and linearity of detection.
Limitations of the radiolabelling approach include (i) lack of
labelling of some proteins due to low turnover, (ii) problems
associated with safety regulations and disposal, and (iii) di⁄-
culties in obtaining fresh human biopsy material for labelling
experiments. Ideally, one would like to have a highly sensitive
£uorescence-based protein detection technique able to support
all types of studies irrespective of the sample, or the end point
of the analysis. Preferably, the dye should not alter the mo-
lecular weight and pI of the proteins if it is to be added prior
to electrophoresis, and should support quantitative studies
involving proteins having extreme di¡erences in their copy
numbers. Unfortunately, no such ideal dye is available on
the market yet, although Oxford GlycoScience has developed
£uorescent IPG^PAGE (http://www.ogs.com/proteome/
home.html), a technology not available to the scienti¢c com-
munity. Fluorescence compounds such as SYPRO Orange,
SYPRO Red and SYPRO Ruby have been used to analyze
whole protein lysates from bacterial and mammalian cells, but
their sensitivity (1^2 ng) is slightly lower than that of silver
nitrate [76,77]. Some advantages over silver staining include
short staining time and the fact that the gels do not need to be
¢xed prior to staining. In addition, little or no destaining is
required.
For low abundance proteins of known identity, detection
does not pose a problem as Celis and co-workers have shown
that 2D PAGE immunoblotting in combination with en-
hanced chemiluminescence (ECL) can detect as little as 100^
500 molecules per cell in unfractionated cellular extracts [60].
3.1.2. Quantitation. Even though there are several tools
available for the quantitation of protein spots, there is at
present no available procedure for quantitating all of the pro-
teins resolved in a complex mixture. Part of the problem lies
in the large dynamic range of protein expression, lack of res-
olution, post-translational modi¢cations, staining behavior of
the proteins, as well as in the fact that many abundant pro-
teins streak over less abundant components interfering with
the measurements. At present, £uorescent technology seems to
be way ahead; as with the £uorescence stain Sypro Ruby
there is a linear response with respect to the sample amount
over a wide range of abundance ([77] and references therein).
Quantitative £uorescence measurements can be performed
with CCD-camera based systems as well as with laser scanner
systems ([77] and references therein). In some cases, radiola-
belling in combination with scintillation counting o¡ers a rea-
sonable alternative for quantitating a small number of pro-
teins [68].
3.1.3. Identi¢cation. Methods of protein identi¢cation
have included immunoblotting [78,79], Edman peptide se-
quencing ([80,81] and references therein), amino acid compo-
sition [82,83], and more recently the use of matrix-assisted
Fig. 3. Non-cultured normal human keratinocyte proteins separated using (A) carrier ampholytes (3.5^10) and (B) IPGs (3^10). A few proteins
are indicated for reference. B is from Bjellqvist et al. [72].
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laser desorption/ionization (MALDI) mass spectrometry [84]
and electrospray ionization (ESI) [85]. The latter techniques,
which rely on the comparison of peptide mass ¢ngerprints, are
fast and require only picomol amounts of proteins. Limited
peptide sequencing can be performed using tandem mass spec-
trometry or post-source decay, but it it is still not possible to
make N- and C-terminal sequence identi¢cation. For a review
on Edman peptide sequencing see reference [81]. Andersen
and Mann review protein identi¢cation by mass spectrometry
elsewhere in this issue.
3.2. Making comprehensive 2D PAGE databases
Advances in hardware and software development (Elsie,
Gellab, Melanie, Quest, Tycho and Kepler) for scanning
and image analysis of 2D gels, as well as the development
of sensitive tools for rapid protein identi¢cation, have cata-
lyzed the establishment of comprehensive proteomic 2D
PAGE databases [64,86]. These databases aim at interfacing
protein information with forthcoming DNA mapping and se-
quence data from genome projects, and o¡er a global ap-
proach to the study of gene expression both in health and
disease (http://biobase.dk/cgi-bin/celis ; http://expasy.hcuge.ch/
sprot/sprot-top.html) ([10,55] and references therein). Besides
annotating genomes, these databases are expected to address
problems that cannot be approached by DNA analysis,
namely, relative abundance of the protein product, post-trans-
lational modi¢cations, subcellular localization, turnover, in-
teraction with other proteins as well as functional aspects.
The ¢rst prototype databases were built by Celis and Bravo
[87], who pioneered the use of protein identi¢cation tech-
niques to establish comprehensive 2D PAGE databases [88].
Fig. 4 shows a region of the synthetic master 2D PAGE
image (isoelectric focusing, IEF) of [35S]methionine labelled
proteins from fresh non-cultured human keratinocytes as de-
picted in the World Wide Web (http://biobase.dk/cgi-bin/
celis). Proteins £agged with a red cross correspond to known
polypeptides that have been identi¢ed by one or a combina-
tion of techniques that include (i) 2D gel immunoblotting
using speci¢c antibodies and the ECL detection procedure,
(ii) microsequencing of Coomassie brilliant Blue stained pro-
teins [89], (iii) mass spectrometry of tryptic peptides [90] and
(iv) comigration with known human proteins (individual pro-
teins and organelle components) and (v) overlay techniques
[59] and (vi) transient expression in mammalian cells [91].
To date, 1237 polypeptides have been identi¢ed in this data-
base (IEF and NEPHGE) of the 3159 that have been resolved
and catalogued. In addition to [35S]methionine labelled pro-
teins, the database contains a few polypeptides that lack me-
thionine, but are revealed by silver staining, Coomassie bril-
liant Blue or by labelling with a mixture of 16 [14C]amino
acids. It should be stressed that some proteins migrate both
in IEF and NEPHGE gels (for example, K-enolase, triose-
phosphate isomerase and elongation factor 2) and they may
serve as landmarks to align the gels and as references to nor-
malize quantitations in both pH directions.
Information gathered on any given polypeptide, known or
unknown, can be retrieved by clicking on the corresponding
spot, in this case 14-3-3 sigma, also known as strati¢n (Fig. 4)
[92]. A ¢le containing all of the information entered for this
particular protein, mostly obtained from experiments per-
formed in our laboratory, is shown in Fig. 5 (only a fraction
of the ¢le is presented). Files for known proteins contain links
Fig. 4. Fraction of the master synthetic image of human keratinocyte proteins separated by IEF 2D PAGE as depicted in the World Wide
Web (http//biobase.dk/cgi-bin/celis). Proteins £agged with a red cross correspond to known proteins. By clicking on any spot it is possible to
obtain a ¢le containing information about the protein as well as links to other sites in the World Wide Web.
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to a subset of Medline (http://www.ncbi.nlm.nih.gov/
PubMed/), Swiss-Prot (http://expasy.hcuge.ch/sprot/sprot-top.
html) and PDB (http://www.embl-heidelberg.de/pdb/). Other
links include OMIM (http://www.ncbi.nlm.nih.gov/ Omim/),
GeneCards (http://bioinformatics.weizmann.ac.il/cards), Uni-
Gene (http://www.ncbi.nlm.nih.gov/UniGene/index.html) and
other Web sites such as CySPID (cytoskeletal protein data-
base; http://paella.med.yale.edu/Vpanzer/cytoskdb/index.
html), metabolic pathways (compiled by KEGG; http://
www.genome.ad.jp/kegg/), the cytokine explorer (http://
kbot.mig.missouri.edu:443/cytokines/explorer.html), histology
images (http://biosun.biobase. dk/Vpdi/jecelis/micrographs.
html), etc. In the future, as new databases and related Web
sites become available, it will be possible to navigate through-
out various databases containing complementary information
(i.e. nucleic acid and protein sequence, genome mapping, dis-
eases, protein structure, post-translational modi¢cations, anti-
bodies, signalling pathways, histology, etc.). Clearly, data-
bases allow easy access to a large body of data: once a
protein is identi¢ed in given databases, all of the information
accumulated can be easily retrieved and made available to the
researcher.
Today, 188 information categories are available in the
World Wide Web version of the keratinocyte database. These
include cellular localization, pathways, proteins a¡ected in
psoriatic keratinocytes, proteins expressed in normal urothe-
lium, keratinocytes, ¢broblasts, HeLa cells and bladder carci-
noma cell line RT4, levels in fetal human tissues, partial ami-
no acid sequences, abundance, cytoskeletal proteins, calcium-
binding proteins, annexins, chaperonins, heat shock proteins,
etc.
Functions to query the databases include search by name,
protein number or keywords (Fig. 4), molecular weight and
pI, as well as by organelle or cellular component. By clicking
on any of the organelles, cellular structures or components it
is possible to get a protein list as well as their relative posi-
tions on the master image. In addition, one can retrieve a list
of all known proteins recorded in the database. Moreover, we
provide protocols and videos of preparative steps that can be
used to reproduce the data displayed as well as a gallery of 2D
gels and immunoblots.
Aarhus 2D PAGE databases available at http://biobase.dk/
cgi-bin/celis include transitional cell carcinomas (TCCs), squa-
mous cell carcinomas (SCCs), urine, ¢broblasts, and mouse
kidney cells. Other databases available in the Internet can be
found in http://expasy.hcuge.ch/sprot/sprot-top.html; http://
www.hare¢eld.nthames.nhs.uk/nhli/protein; and http://user-
page.chemie.fu-berlin.de/Vpleiss/dhzb.html. Also, several
proteomic tools for protein identi¢cation and characteriza-
tion, primary structure analysis, secondary structure predic-
tion, tertiary structure and DNA translation into protein are
available at the EXPASY proteomic server (http://www.expa-
sy.ch/www/tools).
3.3. Applications
To date, there have been thousands of reports illustrating
the usefulness of the 2D PAGE and proteomic technologies in
many areas of biology. Because of space limitations, however,
only a few of the application areas are highlighted below:
3.3.1. Cancer. A great deal of research has been devoted
to the elucidation of the pathways that control cell prolifer-
ation in normal cells, and hence, the determination of the
means by which alterations of these pathways lead to abnor-
mal growth characteristics and/or neoplastic transformation
Fig. 5. Files for the 14-3-3 sigma protein available in the Internet version of the human keratinocyte database. Only a few entries are shown.
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and cancer. Most studies have focused on oncogenes, tumor
suppressors, cell cycle regulated proteins and signal transduc-
tion molecules in various cell types of di¡erent species [93^96],
but only in a few cases there have been systematic attempts to
analyze the protein phenotype of pairs of normal and trans-
formed cell types using a proteomic approach [60,68,97^99].
So far, only very few studies have made use of biopsy material
due to problems related to the cell heterogeneity.
Already in 1982, Celis and co-workers started a proteomic
approach to the study of cell transformation using cloned cell
lines [68,97,98]. Their results showed that transformation re-
sulted in the abnormal expression of normal genes, rather
than in the expression of new ones [98]. In addition, their
studies raised a word of caution concerning the widespread
use of protein information derived from studies of di¡erent
cell types from various species. Today, we are well aware that
cultured cells undergo important changes when placed in cul-
ture due to di¡erent environmental factors and growth con-
ditions [100] and accordingly, current e¡orts using the proteo-
mic approach are being directed to the study of non-cultured
cells and/or tissue biopsies. Among the cancer projects cur-
rently underway, those centered on leukemia and hematolog-
ical malignancies, breast cancer, colorectal cancer and bladder
cancer are brie£y mentioned below.
3.3.1.1. Leukemia and hematological malignancies. Studies
by Hanash and colleagues on childhood leukemia and other
hematological malignancies have yielded so far several
markers that include Op18, also known as stathmin, an
oncoprotein that has been implicated in signal transduction
[101,102]. In childhood leukemia, phosphorylation of Op18
was shown to correlate with a high content of cells in the S-
phase suggesting a role in proliferation. The group also
identi¢ed nm23-H1 (nucleoside diphosphate kinase A), a 19
kDa protein that is upregulated in normal lymphocytes
treated with mitogens as well as in leukemia cells from
patients with acute leukemia [103].
3.3.1.2. Breast cancer. Systematic studies of clinical breast
tumors of di¡erent histopathological types by Franzen and
co-workers [104^106] have revealed several proteins, including
PCNA, hsp60, hsp90 and calreticulin that are highly deregu-
lated in invasive carcinomas and that may serve as prognostic
markers. These studies have made use of fresh clinical tumor
tissues of di¡erent subtypes and have paid special attention to
sample preparation.
3.3.1.3. Colorectal cancer. Studies of Jungblut and col-
leagues [107^109] on sets of macroscopically normal colon
mucosa and colorectal carcinomas have revealed several pro-
teins that are deregulated in the tumors. Downregulated pro-
teins included the liver fatty acid binding protein, the smooth
muscle protein 22-K, and cyclooxygenase 2. Upregulated pro-
teins included the heat shock protein 70 as well as several
members of the S-100 family of calcium-binding proteins (S-
100A9, S-100 A8, S100A11 and S-100A6). Some of these ¢nd-
ings have been con¢rmed by immunohistochemical studies
[108].
3.3.1.4. Bladder cancer. Celis and colleagues [110^112]
have explored the possibility of using proteome expression
pro¢les of bladder tumors as ¢ngerprints to subclassify histo-
pathological types, and as a starting point for searching for
protein markers that may form the basis for diagnosis, prog-
nosis and treatment. To achieve these goals they have ana-
lyzed the proteome expression pro¢les of hundreds of fresh
tumors as well as random biopsies and cystectomies [110^112],
and have established TCC and SCC proteomic databases that
may provide a solid infrastructure to support future studies
([113] ; http://biobase.dk/cgi-bin/celis). In the long run, a prac-
tical goal of these studies is to identify a complete set of
protein biomarkers that may be useful to classify histopatho-
logical grades, and that will provide with speci¢c probes for
the objective diagnosis, prognosis and treatment of these le-
sions. So far, these studies have revealed markers for TCC
progression [110], a marker in the urine of patients bearing
SCCs [114,115], and have led to the development of a novel
strategy for identifying premalignant squamous lesions [112].
The approach makes use ¢rst of proteomic technologies to
reveal and identify proteins that are di¡erentially expressed
in pure SCCs and normal urothelium. Thereafter, speci¢c
antibodies against the di¡erentially expressed proteins are
used to immunostain serial cryostat sections of biopsies (im-
munowalking) obtained from SCC patients that have under-
gone removal of the bladder due to invasive disease (cystec-
tomy). Since bladder cancer is a ¢eld disease [116] ^ that is
large part of the bladder lining is at risk of developing disease
^ it is expected that the urothelium of these patients may
exhibit a spectrum of abnormalities ranging from metaplasia
to invasive disease.
3.3.2. Heart diseases. Heart failure is among the leading
causes of mortality in the Western Hemisphere and therefore,
e¡orts are being devoted to the elucidation of the molecular
events leading to cardiac dysfunction ([117] and references
therein). So far, research on dilated cardiomyopathy (DCM)
[117^119], has revealed that approximately 100 proteins are
deregulated, mostly downregulated, in DCM as compared to
their normal counterparts. These include cytoskeletal and my-
o¢brillar proteins, polypeptides associated with mitochondria
and involved in energy production, as well as proteins asso-
ciated with the stress response. These studies have been expe-
dited by the establishment of proteomic 2D PAGE databases
of the human heart (ventricle and atrium) [120]
In addition to the global analysis of protein expression
patterns in human heart diseases, cardiac antigen expression
following cardiac transplantation has also been studied using
techniques from proteomics. For example, using 2D PAGE
(cardiac proteins) in combination with Western immunoblot-
ting (patient sera), it has been possible to identify antigens
that react with autoantibodies present both in DCM
[121,122] and myocarditis [123]. In this way, antigens associ-
ated with the antibody response that may be involved in acute
or chronic organ rejection have been characterized.
Proteomic studies using animal models of heart disease
have also been carried out in an e¡ort to unravel the molec-
ular events leading to cardiac disease. Recently, two di¡erent
studies involving large animals, pace-induced heart failure in
the dog [124] and bovine DCM [125], yielded similar results as
those observed in human DCM. Interestingly, the most strik-
ing result in the bovine DCM study was the ¢nding of a
seven-fold decrease in the expression level of ubiquitin C-ter-
minal hydrolase, as inappropriate ubiquination of proteins
has been suggested as an etiologic factor in heart failure [126].
3.3.3. Toxicology. Changes in the environment as well as
the growing interest of the pharmaceutical industry have
stimulated the development of novel testing approaches based
on the recent technical advances both in genomics and pro-
teomics. Pioneering studies by Anderson and Anderson [127]
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have highlighted the usefulness and potential of the proteomic
approach to identify quantitative changes in rat liver expres-
sion pro¢les associated with toxicity of drugs and other xeno-
biotics. The data, which are being systematically stored in the
rodent molecular e¡ects database, are expected to yield im-
portant information as to the molecular mechanisms under-
lying toxic responses. Likewise, the potential of proteomics
have been recently exempli¢ed in studies of glomerular neph-
rotoxicity in rats [128], and of stimulated occupational jet fuel
exposure in mice lung [129]. In particular, the studies of Stein-
er’s group have shown a remarkable correlation between de-
creased levels of calbindin D-28, urinary calcium wasting in
the urine, and intratubular corticomedullary calci¢cations in
the kidney of rats and human treated with cyclosporin A
[130].
In the future, proteomics in a high-throughput mode is
expected to have a major impact in the pre-clinical safety
testing of drugs. These studies will be facilitated by the estab-
lishment of 2D PAGE databases of frequent target tissues
(kidney, liver) as well as of cell lines and £uids.
3.3.4. Neurological disorders. The Creutzfeld^Jacob dis-
ease (CJD) has been the subject of intensive analysis using
proteomics. These studies have led to the identi¢cation of
two members of the14-3-3 family of proteins in the cerebral
spinal £uid (CSF) of CJD patients [131]. The presence of these
proteins in the CSF has been used to di¡erentiate CJD from
other dementia both with high sensitivity and speci¢city
[132,133]. These proteins, however, are present in the CSF
of patients su¡ering from other neurological disorders not
involving dementia, limiting its clinical value [134,135].
3.4. Conclusions
Today, there is no technology in sight that matches the
resolving power of 2D PAGE, a technique that will continue
to enjoy a central position in proteomic projects for some time
in the near future. There is considerable room for improve-
ment, however, in particular as far as sample preparation and
solubility, choice of pH gradient and detection methods are
concerned. Also, we need to improve the separation of very
basic as well as very low and high molecular weight polypep-
tides. In general, one expects researchers to ¢rst use wide IPG
gradients to obtain an overview of the proteome pro¢les, and
then proceed with a more detailed analysis using narrow pH
gradients, which provide higher resolution and sample load-
ing, thus increasing the possibility of visualizing the lesser
abundant proteins. The latter can be facilitated by the avail-
Fig. 6. 2D PAGE (A and B) and chip data (C and D) on the expression of keratin 8 in a non-invasive (grade II, Ta) and an invasive TCC
(grade III, T1). C and D: The top row shows reaction with perfect match probes, the lower row shows reaction with mismatch control probes.
E: Immunoblot of the proteins resolved in A reacted with antibodies against keratin 8. The position of keratin 8 and of one of its degradation
products is indicated for reference. F: MALDI-TOF peptide ¢ngerprint of the keratin 8 degradation product indicated in A and E.
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ability of speci¢c antibodies, as well as by the use of extrac-
tion procedures and subcellular fractionation methods cur-
rently at hand [136^138].
There are still many additional challenges, however, that
must be addressed before a complete Human Proteome Proj-
ect can be implemented [139]. These include: automation to
allow high-throughput sample analysis [140], improved quan-
titation capabilities, better instrumentation and software for
peptide sequencing using mass spectrometry, more sophisti-
cated image analysis systems to support gel comparisons
and databasing as well as improved bioinformatic capabilities
overall [12]. In addition, we need to deal with the problem of
tissue cell heterogeneity as more and more proteomic projects
will make use of biopsy material in the future.
4. Transcript and protein levels : DNA microarrays and
proteomics applied to the same samples
As mentioned in Section 1, both DNA microarrays and
proteomics are complementary technologies. To date, how-
ever, there have been only a limited number of studies in
which both technologies have been compared by applying
them to the same sample [141,142]. Notably, the pioneer stud-
ies of Anderson and Seilhamer [52] showed that there is not a
good correlation between mRNA and protein levels in human
liver, implying that gene-based expression data may be of
limited value in the process of drug discovery. The study,
which compared the levels of 19 gene products, yielded a
correlation coe⁄cient of 0.48 between mRNA and protein
abundance, a value that is half way between perfect and no
correlation.
Recently, Òrntoft et al. (manuscript in preparation) carried
out a microarray and proteomic study of bladder cancer in
which they compared the transcript and protein expression
levels of pairs of non-invasive and invasive low grade fresh
TCCs. Even though they could only compare the levels of
about 40 well-resolved and focused abundant proteins, it
was clear that in most cases there was a good correlation
between transcript and protein levels. Only in a few cases
they found discrepancies, and in some of those instances
they could not eliminate the possibility that this was due to
messenger stability, post-transcriptional splicing, post-transla-
tional modi¢cations, protein focusing problems, degradation,
as well as the choice of methods used to assess protein ex-
pression levels (staining versus radiolabelling). For example,
in one tumor pair they found that the levels of keratin 8
transcripts were much higher in the invasive tumor (compare
Fig. 6C and D), while the protein levels were much lower
(compare Fig. 6A and B). Immunoblotting analysis using ker-
atin 8 speci¢c antibodies revealed that the discrepancy was
due to degradation, as several related products of lower ap-
parent molecular weights and more acidic pIs, could be visu-
alized (Fig. 6E). The identity of one of the crossreacting
peptides (indicated with arrows in Fig. 6E) to keratin 8
was further con¢rmed by MALDI-time-of-£ight (TOF) (Fig.
6F). From these studies it was clear that when comparing
mRNA and protein levels there are other factors that
need to be taken into consideration when interpreting the
data.
When comparing transcripts and protein expression pro¢les
of matched sample pairs one often gets the impression that
there are more changes in the abundance of the mRNA tran-
scripts as compared to the proteins. Considering that the cur-
rent 2D PAGE technology depicts mainly the more abundant
proteins, it would seem possible that most of the changes
a¡ecting protein levels may involve low abundance polypep-
tides.
5. Gene expression pro¢ling techniques: perspectives
Novel and powerful techniques are now available to analyze
the global gene expression patterns of cultured cells and tis-
sues obtained from normal and diseased subjects. Each of
these technologies has its own advantages and limitations,
but in combination they should provide us with a detailed
gene expression phenotype at both the transcription and
translation level. A major challenge in the near future will
be to de¢ne a base line for the normal gene expression phe-
notype of a given cell type, tissue or body £uid. This is not a
trivial task, however, as it will require the analysis of hun-
dreds or even thousands of samples.
Besides improvements on the individual techniques them-
selves (see above), there are still major limitations that must
be addressed before these technologies can provide the
expected outcome in molecular medicine. These include:
(i) technical problems associated with the analysis of expres-
sion pro¢les derived from tissues that are composed of di¡er-
ent cell types, (ii) lack of procedures for identifying targets
that lie in the pathway of disease, and (iii) need for bioinfor-
matics tools for rapidly assessing the function of the putative
targets. The latter is of paramount importance to the phar-
maceutical industry as the identi¢cation of disease deregulated
targets alone is not su⁄cient to start a costly drug screening
process.
As far as tissue heterogeneity is concerned, the recent ad-
vent of LCM holds great promise as with this technique it is
possible to isolate speci¢c populations of cells from a tissue
section using direct microscopic observation [29]. However,
even though the technique has been used for RNA analysis
it is still not ready for most proteomic projects as the number
of cells that can be obtained is too small to generate reason-
able protein pro¢les in terms of the number of proteins that
can be visualized [143].
As DNA microarrays and proteomics generate more data in
the future it will become a matter of priority to develop simple
and rapid strategies to validate the vast amount of informa-
tion that will be generated, particularly in tissue biopsies. This
we believe can be accomplished in part by making use of
speci¢c antibodies in combination with immunohistochemistry
[112]. At present, there is no technology at hand that may
allow us to prepare antibodies at will, although phage anti-
body libraries [14] show much promise.
Finally, we would like to emphasize that biology in this
Millennium will be characterized by the study of complex
biological phenomena. DNA microarrays and proteomics
are just some of the technologies of functional genomics,
and only their integration may allow us to tackle the great
complexity underlying biological processes.
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